ClinicalTrials.gg
CompletedNCT03005288Updated Jan 5, 2021Results posted

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

A Phase 2 interventional study of BYM338 10 mg/kg and Placebo in Diabetes Mellitus, Type 2, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies in Diabetes Mellitus, Type 2 by Novartis — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Novartis.

Enrollment
86th of 121
78 · median 183
Started
2017
with 2 others
Phase 2
13 of 122
none open now
Registered
119th of 122
by date

Among the 122 studies in Diabetes Mellitus, Type 2 by Novartis, this one is the 86th largest by enrollment of the 121 interventional ones that give a count, is one of 3 that started in 2017, is one of 13 in phase 2, and was the 119th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 122 studies in Diabetes Mellitus, Type 2 by Novartis is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 122 studies in Diabetes Mellitus, Type 2 by Novartis as a file.
02

Study summary

This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes

Read the detailed description

A non-confirmatory, randomized, subject and investigator blinded, placebo controlled, parallel-arm study, investigating a 48-week treatment period with i.v. bimagrumab 10 mg/kg in overweight and obese subjects with type 2 diabetes.

Participants were randomized and assigned to one of the following 2 treatment arms in a ratio of 1:1:

Arm 1: Bimagrumab 10 mg/kg up to maximum 1200 mg, every 4 weeks (12 doses) until week 44.

Arm 2: Placebo, every 4 weeks (12 doses) until week 44.

The study consisted of a screening baseline period of 3 weeks, treatment period of 48 weeks and then a follow-up period of 8 weeks.

Treatment period visits were scheduled every 4 weeks until week 44. Administration of bimagrumab or placebo was done via an i.v. infusion over 30 minutes followed by flushing for 15 minutes. Subjects were asked to return to the Investigator site for dosing approximately every 4 weeks during the treatment period. During those visits, subjects were evaluated for safety, tolerability, PK and efficacy. The treatment period ended approximately 4 weeks after the last dose administration.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • type 2 diabetes
  • obesity
  • DXA
  • MRI
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes with between 6.5% and 10% at screening with stable treatment for 3 months prior to randomization
  • On one of the following anti-diabetes regimens with stable treatment for approximately 3 months prior to randomization: 1) metformin monotherapy; 2) DPP4 inhibitor agent monotherapy; 3) combination therapy of metformin and DPP4 inhibitor agent; 4) no anti-diabetes therapy.
  • of 28 to 40 kg/m2 at screening
  • Body weight between 65 and 140 kg at screening

Exclusion criteria

Exclusion Criteria:

  • Women of unless they are using highly effective methods of
  • Diabetes other than Type 2 such as Type 1 diabetes, surgically induced diabetes, "brittle" type 2 diabetes as per investigator judgement, history of severe hypoglycemic episodes in the year preceding screening or hypoglycemic unawareness
  • History of arrythmias, heart failure, unstable angina, myocardial infarction or stroke, coronary artery bypass graft surgery, or percutaneous coronary intervention, deep vein thrombosis/pulmonary embolism, valve disorders or defects, pulmonary hypertension within 6 months of screening or 1 year for drug-eluting stents
  • Tachycardia
  • Use of anti-obesity medications, nutritional supplements or over the counter products for weight loss within 3 months of screening
  • Use of medications known to induce weight gain such as some anti-convulsant and psychotropic medications within 3 months of screening
  • Any chronic active infection (e.g., , or C, tuberculosis, etc) or has received anti- treatments within the previous 6 months.
  • Uncontrolled thyroid disease. Stable euthyroid patients on stable thyroid replacement therapy for at least 3 months of screening are allowed.
  • Abnormal liver function tests such as , SGPT, alkaline phosphatase, or serum , or abnormal lipase and/or amylase.
  • Known history or presence of severe active acute or chronic liver disease (e.g., cirrhosis).
  • Uncontrolled depression
  • Use of skeletal muscle anabolic agents in any form for 3 months prior to screening
  • Chronic kidney disease [estimated (GFR) \< 30 mL/min];
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    BYM338 10 mg/kg

    Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)

    Drug: BYM338 10 mg/kg

  • Placebo comparator
    Placebo

    Placebo, every 4 weeks until week 44 (12 doses)

    Other: Placebo

Interventions

  • DrugBYM338 10 mg/kg

    Drug page: Bimagrumab

    intravenous infusion every four weeks

    Also known as: Bimagrumab

  • OtherPlacebo

    intravenous infusion every four weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48

    Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24

    Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.

    Time frame: Baseline, Week 24

  2. Change From Baseline in HbA1c at Week 24 and 48

    HbA1c reflects average glucose concentrations over the past 3 months and therefore provides a useful index of the glycemic control of bimagrumab over that time period. It is a standard endpoint used to assess the glycemic efficacy of any anti-diabetic medication. HbA1c is a key glycemic parameter which correlates with reduction of risk of diabetic complications.

    Time frame: Baseline, Week 24, Week 48

  3. The Trough Observed Analyte Concentration (Ctrough) of Repeat Doses of BYM338 10 mg/kg on Day 84, 168, 252, 308 and 336

    The trough observed analyte concentration (Ctrough) is the concentration that is just prior to the beginning of, or at the end of, a dosing interval (μg/mL).

    Time frame: Day 84, 252, 336 at pre-dose only. Day 168, 308 at pre-dose and 45 mins post-dose

  4. Maximum Observed Serum Concentration(Cmax) Derived on Day 1, 168 and 308

    Cmax is the observed maximum plasma concentration following administration (μg/mL).

    Time frame: Day 1, 168, 308 at pre-dose and 45 mins post-dose

  5. Time to Reach the Maximum Concentration After Drug Administration (Tmax) Derived on Day 168 and 308

    Tmax is the time to reach peak or maximum concentration (h) after the drug administration.

    Time frame: Day 1, 168, 308 at pre-dose and 45 mins post-dose

  6. Change From Baseline in Body Mass Index (BMI)

    Body Mass Index (BMI) was determined by height and weight measurements at week 24 and 48. A negative change from baseline indicates improvement. BMI was calculated as (Body weight (kg)/ \[Height (m)\]\^2)

    Time frame: Baseline, Week 24, Week 48

  7. Change From Baseline in Weight

    Body weight was measured to the nearest 0.1 kilogram (kg) in indoor clothing without shoes. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 24, Week 48

  8. Change From Baseline in Lean Body Mass (LBM) Measured by DXA

    Lean body mass (LBM) is a part of body composition defined as the difference between total body weight and body fat weight. This means that it counts the mass of all organs except body fat, including bones, muscles, blood, skin, and everything else. Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.

    Time frame: Baseline, Week 24, Week 48

  9. Change From Baseline in Waist Circumference

    Waist circumference is the length in cm of the circumference to the nearest 0.1 cm at the level of the umbilicus with the subject in the upright position. A negative change indicates improvement.

    Time frame: Baseline, Week 24, Week 52

  10. Change From Baseline in Waist to Hip Ratio

    Hip circumference was measured at the greatest protrusion of the buttocks. Combined with waist circumference, the waist-to-hip ratio was derived during data analysis.

    Time frame: Baseline, Week 24, Week 52

  11. Change From Baseline in Insulin Resistance (HOMA2-IR)

    Blood samples were collected to analyze insulin resistance. The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). Higher numbers indicate higher insulin resistance. No established cutoffs are indicating impaired resistance. HOMA2-IR was calculated using an online calculator \[https://www.dtu.ox.ac.uk/homacalculator/\].

    Time frame: Baseline. Week 12, Week 36

  12. Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial

    Describes the number of participants tested positive for anti-BYM338 antibodies after the start of bimagrumab (BYM338) treatment. A validated bridging enzyme-linked immunosorbent assay (ELISA) was used for the confirmation of the presence of anti-BYM338 antibodies in human serum.

    Time frame: 392 days

07

Results

Posted Jun 4, 2020

Participant flow

The study was completed as planned.

Participant flow — Overall Study
MilestoneBYM338 10 mg/kgPlacebo
Started3939
Safety analysis set3738
Pharmacokinetics (pk) analysis set360
Pharmacodynamics (pd) analysis set3636
Completed2731
Not completed128
Withdrew: Withdrawal by subject75
Withdrew: Lost to follow-up01
Withdrew: Adverse event50
Withdrew: Protocol deviation01
Withdrew: Physician decision01

Outcome measures

PrimaryChange From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48

Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · kg
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48
kgBYM338 10 mg/kgPlacebo
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48-7.49 (-8.33 to -6.64)-0.18 (-0.99 to 0.63)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -7.31 · 80% CI -8.48 to -6.14
SecondaryChange From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24

Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kg
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24
kgBYM338 10 mg/kgPlacebo
Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 24-5.37 (-5.96 to -4.78)-0.18 (-0.75 to 0.39)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -5.19 · 80% CI -6.01 to -4.37
SecondaryChange From Baseline in HbA1c at Week 24 and 48

HbA1c reflects average glucose concentrations over the past 3 months and therefore provides a useful index of the glycemic control of bimagrumab over that time period. It is a standard endpoint used to assess the glycemic efficacy of any anti-diabetic medication. HbA1c is a key glycemic parameter which correlates with reduction of risk of diabetic complications.

Time frame:
Baseline, Week 24, Week 48
Reported as:
Least squares mean · percentage change
Change From Baseline in HbA1c at Week 24 and 48
percentage changeBYM338 10 mg/kgPlacebo
week 24-0.85 (-1.06 to -0.64)0.28 (0.08 to 0.48)
week 48-0.76 (-1.05 to -0.48)0.04 (-0.23 to 0.31)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (net): -1.13 · 80% CI -1.42 to -0.83
  • BYM338 10 mg/kg vs Placebo · Mixed Models Analysis · p = 0.005 · Mean difference (net): -0.80 · 80% CI -1.20 to -0.41
SecondaryThe Trough Observed Analyte Concentration (Ctrough) of Repeat Doses of BYM338 10 mg/kg on Day 84, 168, 252, 308 and 336

The trough observed analyte concentration (Ctrough) is the concentration that is just prior to the beginning of, or at the end of, a dosing interval (μg/mL).

Time frame:
Day 84, 252, 336 at pre-dose only. Day 168, 308 at pre-dose and 45 mins post-dose
Reported as:
Mean · μg/mL
The Trough Observed Analyte Concentration (Ctrough) of Repeat Doses of BYM338 10 mg/kg on Day 84, 168, 252, 308 and 336
μg/mLBYM338 10 mg/kgPlacebo
Day 8425.3 ± 6.20—
Day 16827.5 ± 8.37—
Day 25231.0 ± 11.2—
Day 30829.9 ± 11.0—
Day 33627.8 ± 10.9—
SecondaryMaximum Observed Serum Concentration(Cmax) Derived on Day 1, 168 and 308

Cmax is the observed maximum plasma concentration following administration (μg/mL).

Time frame:
Day 1, 168, 308 at pre-dose and 45 mins post-dose
Reported as:
Mean · μg/mL
Maximum Observed Serum Concentration(Cmax) Derived on Day 1, 168 and 308
μg/mLBYM338 10 mg/kgPlacebo
Day 1283 ± 32.0—
Day 168292 ± 45.3—
Day 308271 ± 31.1—
SecondaryTime to Reach the Maximum Concentration After Drug Administration (Tmax) Derived on Day 168 and 308

Tmax is the time to reach peak or maximum concentration (h) after the drug administration.

Time frame:
Day 1, 168, 308 at pre-dose and 45 mins post-dose
Reported as:
Median · hr
Time to Reach the Maximum Concentration After Drug Administration (Tmax) Derived on Day 168 and 308
hrBYM338 10 mg/kgPlacebo
Day 10.750 (0.683 to 0.917)—
Day 1680.750 (0.750 to 1.05)—
Day 3080.750 (0.750 to 1.38)—
SecondaryChange From Baseline in Body Mass Index (BMI)

Body Mass Index (BMI) was determined by height and weight measurements at week 24 and 48. A negative change from baseline indicates improvement. BMI was calculated as (Body weight (kg)/ \[Height (m)\]\^2)

Time frame:
Baseline, Week 24, Week 48
Reported as:
Least squares mean · Kg/m^2
Change From Baseline in Body Mass Index (BMI)
Kg/m^2BYM338 10 mg/kgPlacebo
week 24-1.50 (-1.77 to -1.23)-0.17 (-0.43 to 0.10)
week 48-2.19 (-2.60 to -1.78)-0.28 (-0.67 to 0.11)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -1.33 · 80% CI -1.71 to -0.95
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -1.91 · 80% CI -2.48 to -1.34
SecondaryChange From Baseline in Weight

Body weight was measured to the nearest 0.1 kilogram (kg) in indoor clothing without shoes. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 24, Week 48
Reported as:
Least squares mean · Kg
Change From Baseline in Weight
KgBYM338 10 mg/kgPlacebo
week 24-3.99 (-4.79 to -3.19)-0.57 (-1.34 to 0.21)
week 48-5.90 (-7.08 to -4.71)-0.79 (-1.92 to 0.33)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -3.43 · 80% CI -4.54 to -2.31
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -5.10 · 80% CI -6.74 to -3.47
SecondaryChange From Baseline in Lean Body Mass (LBM) Measured by DXA

Lean body mass (LBM) is a part of body composition defined as the difference between total body weight and body fat weight. This means that it counts the mass of all organs except body fat, including bones, muscles, blood, skin, and everything else. Dual energy X-ray absorptiometry (DXA) was used to assess changes in body composition, including total fat and lean body mass (FM and LBM) and appendicular skeletal fat and muscle mass (aFM and aLBM). DXA instruments had a source that generated x-rays split into two energies which measured bone mineral mass and soft tissue from which fat and fat-free mass (or lean body mass) were estimated.

Time frame:
Baseline, Week 24, Week 48
Reported as:
Least squares mean · Kg
Change From Baseline in Lean Body Mass (LBM) Measured by DXA
KgBYM338 10 mg/kgPlacebo
week 241.72 (1.25 to 2.19)0.23 (-0.23 to 0.68)
week 481.70 (1.14 to 2.26)-0.44 (-0.97 to 0.09)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = 0.003 · Mean difference (net): 1.49 · 80% CI 0.82 to 2.06
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): 2.14 · 80% CI 1.36 to 2.93
SecondaryChange From Baseline in Waist Circumference

Waist circumference is the length in cm of the circumference to the nearest 0.1 cm at the level of the umbilicus with the subject in the upright position. A negative change indicates improvement.

Time frame:
Baseline, Week 24, Week 52
Reported as:
Least squares mean · cm
Change From Baseline in Waist Circumference
cmBYM338 10 mg/kgPlacebo
week 24-5.04 (-5.87 to -4.20)-0.95 (-1.75 to -0.14)
week 52-9.00 (-10.3 to -7.68)0.45 (-0.79 to 1.69)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -4.09 · 80% CI -5.26 to -2.92
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -9.46 · 80% CI -11.3 to -7.64
SecondaryChange From Baseline in Waist to Hip Ratio

Hip circumference was measured at the greatest protrusion of the buttocks. Combined with waist circumference, the waist-to-hip ratio was derived during data analysis.

Time frame:
Baseline, Week 24, Week 52
Reported as:
Least squares mean · ratio
Change From Baseline in Waist to Hip Ratio
ratioBYM338 10 mg/kgPlacebo
week 24-0.02 (-0.03 to -0.01)-0.01 (-0.01 to 0.00)
week 52-0.05 (-0.06 to -0.04)0.01 (0.00 to 0.02)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = 0.062 · Mean difference (net): -0.02 · 80% CI -0.03 to -0.00
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = <0.001 · Mean difference (net): -0.06 · 80% CI -0.08 to -0.04
SecondaryChange From Baseline in Insulin Resistance (HOMA2-IR)

Blood samples were collected to analyze insulin resistance. The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). Higher numbers indicate higher insulin resistance. No established cutoffs are indicating impaired resistance. HOMA2-IR was calculated using an online calculator \[https://www.dtu.ox.ac.uk/homacalculator/\].

Time frame:
Baseline. Week 12, Week 36
Reported as:
Least squares mean · Insulin Resistance (IR) Score
Change From Baseline in Insulin Resistance (HOMA2-IR)
Insulin Resistance (IR) ScoreBYM338 10 mg/kgPlacebo
week 120.10 (-0.17 to 0.37)0.76 (0.50 to 1.02)
week 36-0.09 (-0.44 to 0.25)0.57 (0.24 to 0.90)
Statistical analysis
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = 0.028 · Mean difference (net): -0.65 · 80% CI -1.03 to -0.28
  • BYM338 10 mg/kg vs Placebo · Mixed-Effect Model Repeated Measure · p = 0.081 · Mean difference (net): -0.66 · 80% CI -1.14 to -0.18
SecondaryImmunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial

Describes the number of participants tested positive for anti-BYM338 antibodies after the start of bimagrumab (BYM338) treatment. A validated bridging enzyme-linked immunosorbent assay (ELISA) was used for the confirmation of the presence of anti-BYM338 antibodies in human serum.

Time frame:
392 days
Reported as:
Count of participants · Participants
Immunogenicity Assessed by the Number of Participants Developing Anti-BYM338 Antibodies During the Trial
ParticipantsBYM338 10 mg/kgPlacebo
Confirmed with positive immunogenicity24

Adverse events

Collected over Adverse events were collected throughout the study for 56 weeks which includes the treatment period of 48 weeks and the follow-up period of 8 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BYM338 10 mg/kg0/37 (0%)3/37 (8.1%)31/37 (83.8%)
Placebo0/38 (0%)3/38 (7.9%)31/38 (81.6%)
Most frequent serious events
Most frequent serious events
EventBYM338 10 mg/kgPlacebo
Abdominal pain upperGastrointestinal disorders1/370/38
PancreatitisGastrointestinal disorders1/370/38
PneumoniaInfections and infestations1/370/38
Lipase increasedInvestigations1/370/38
Acute coronary syndromeCardiac disorders0/371/38
Acute myocardial infarctionCardiac disorders0/371/38
Impaired gastric emptyingGastrointestinal disorders0/371/38
CellulitisInfections and infestations0/371/38
Thermal burnInjury, poisoning and procedural complications0/371/38
Most frequent other events
Showing 10 of 116
Most frequent other events
EventBYM338 10 mg/kgPlacebo
DiarrhoeaGastrointestinal disorders15/374/38
Muscle spasmsMusculoskeletal and connective tissue disorders15/371/38
Upper respiratory tract infectionInfections and infestations6/375/38
HeadacheNervous system disorders0/375/38
NauseaGastrointestinal disorders4/370/38
Lipase increasedInvestigations4/372/38
AnaemiaBlood and lymphatic system disorders3/370/38
HypertensionVascular disorders3/371/38
MyalgiaMusculoskeletal and connective tissue disorders0/373/38
Abdominal painGastrointestinal disorders2/371/38

Baseline characteristics

A total of 78 participants were randomized and were assigned to the respective treatment groups. Of the 78 participants, 3 withdrew from the study prior to dosing due to subject/physician decision. The remaining 75 participants underwent baseline assessments and treatment analysis.

Age, Continuous
Age, Continuous(Years)BYM338 10 mg/kgPlaceboTotal
Mean60.7 ± 7.5060.2 ± 8.0260.4 ± 7.72
Sex: Female, Male
Sex: Female, Male(Participants)BYM338 10 mg/kgPlaceboTotal
Female231235
Male142640
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BYM338 10 mg/kgPlaceboTotal
Race — Black Or African American6915
Race — Other101
Race — White302757
Race — Asian011
Race — Unknown011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BYM338 10 mg/kgPlaceboTotal
Ethnicity — Hispanic Or Latino272552
Ethnicity — Not Hispanic Or Latino91221
Ethnicity — Not Reported112
08

Study locations

9 sites
  • Novartis Investigative Site
    Anaheim, California 92801, United States
  • Novartis Investigative Site
    Miami Lakes, Florida 33014, United States
  • Novartis Investigative Site
    Miami, Florida 33126, United States
  • Novartis Investigative Site
    Miami, Florida 33143, United States
  • Novartis Investigative Site
    Orlando, Florida 32804, United States
  • Novartis Investigative Site
    Baton Rouge, Louisiana 70808, United States
  • Novartis Investigative Site
    Berlin, New Jersey 08009, United States
  • Novartis Investigative Site
    Eatontown, New Jersey 07724, United States
  • Novartis Investigative Site
    Merthyr Tydfil, Mid Glamorgan CF484DR, United Kingdom
09

References and documents

Publications

  • Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, Praestgaard J, Swan T, Wade T, Perry RG, Goodpaster BH, Roubenoff R. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457. Erratum In: JAMA Netw Open. 2021 Feb 1;4(2):e211376. doi: 10.1001/jamanetworkopen.2021.1376. JAMA Netw Open. 2021 Mar 1;4(3):e212581. doi: 10.1001/jamanetworkopen.2021.2581. PubMed 33439265 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Mar 2019, 25 months.

Results were first posted in Jun 2020, 1 year 2 months after primary completion. A results delay was requested in Aug 2019.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 25 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2016
First posted
Dec 29, 2016
StartActual
Feb 1, 2017
Primary completionActual
Mar 21, 2019
CompletionActual
May 8, 2019
Results delay requested
Aug 22, 2019
Results first posted
Jun 4, 2020
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03005288
Responsible party
Sponsor
First posted
Dec 29, 2016
Start date
Feb 1, 2017
Primary completion
Mar 21, 2019
Completion
May 8, 2019
Results posted
Jun 4, 2020
Last update
Jan 5, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimagrumab

Start the discussion